

CURRICULUM VITAE**1. ΠΡΟΣΩΠΙΚΑ ΣΤΟΙΧΕΙΑ**

Όνομα: ΓΕΩΡΓΙΟΣ
Επίθετο: ΚΟΛΙΟΣ
Όνομα Πατρός: ΧΡΗΣΤΟΣ
Ημερομηνία γεννήσεως: 05.05.1955
Τόπος γεννήσεως: Άρτα
Υπηκοότης: Ελληνική
Διεύθυνση: Τμήμα Ιατρικής, Δημοκρίτειο Πανεπιστήμιο Θράκης
Δραγάνα, Αλεξανδρούπολη, 68100
Τηλ.: +3025510-30368 FAX: +3025510-30541
E-mail: gkolios@med.duth.gr

2. ΠΑΡΟΥΣΕΣ ΘΕΣΕΙΣ

- i) Καθηγητής Φαρμακολογίας, Τμήμα Ιατρικής, Δημοκρίτειο Πανεπιστήμιο Θράκης (Ιούνιος 2008 - σήμερα).
- ii) Διευθυντής του Εργαστηρίου Φαρμακολογίας του Τμήματος Ιατρικής του Δ.Π.Θ. και του Εργαστηρίου Κλινικής Φαρμακολογίας του Πανεπιστημιακού Γενικού Νοσοκομείου Αλεξανδρούπολης (Σεπτέμβριος 2008- σήμερα).
- iii) Διευθυντής Σπουδών του Μεταπτυχιακού Προγράμματος «Κλινική Φαρμακολογία-Θεραπευτική» (Σεπτέμβριος 2009-σήμερα).
- iv) Μέλος Α' Επιστημονικού Συμβουλίου Εγκρίσεων, Εθνικός Οργανισμός Φαρμάκων (Σεπτέμβριος 2008 – σήμερα).
- v) Visiting Professor, Department of Pharmacy and Pharmacology, University of Bath, UK (Ιανουάριος 2001 – σήμερα).

3. ΠΑΝΕΠΙΣΤΗΜΙΑΚΕΣ ΣΠΟΥΔΕΣ

1973-1980 Ιατρική Σχολή Πανεπιστημίου Αθηνών, Πτυχίο Ιατρικής, Μάρτιος 1980.

4. ΜΕΤΑΠΤΥΧΙΑΚΟΙ ΤΙΤΛΟΙ

- i) Τίτλος Ιατρικής Ειδικότητας Γαστρεντερολογίας, Μάιος 1990
- ii) Διδακτορική Διατριβή, Ιατρική Σχολή Πανεπιστημίου Αθηνών, Μάιος 1992.
- iii) Διδακτορική Διατριβή (Doctor of Philosophy, PhD in Pharmacology), Σχολή Φαρμακολογίας, Πανεπιστήμιο του Bath, Αγγλία, Φεβρουάριος 1998.

5. ΘΕΣΕΙΣ ΣΤΗΝ ΕΛΛΑΔΑ

- i) Ειδικευόμενος στην Παθολογία, Β' Παθολογική Κλινική του 401 Γεν. Στρατιωτικού Νοσοκομείου Αθηνών, Αύγουστος 1981 – Οκτώβριος 1982.
- ii) Ειδικευόμενος στην Παθολογία, Β' Παθολογική Κλινική του Σισμανογλείου Γενικού Νοσοκομείου Αθηνών, Φεβρουάριος 1985 – Φεβρουάριος 1986.
- iii) Ειδικευόμενος στην Γαστρεντερολογία, Β' Παθολογική Κλινική του Πανεπιστημίου Αθηνών, Ιπποκράτειο Γενικό Νοσοκομείο, Απρίλιος 1986 – Μάρτιος 1990.
- iv) Επιμελητής Β' Γαστρεντερολογικό Τμήμα, Ιπποκράτειο Γενικό Νοσοκομείο Αθηνών, Μάιος 1991 – Ιανουάριος 1998.
- v) Επίκουρος Καθηγητής Γαστρεντερολογίας Πανεπιστημίου Κρήτης, Μάρτιος 2001 – Μάρτιος 2005.

- vi) Μόνιμος Επίκουρος Καθηγητής Γαστρεντερολογίας Πανεπιστημίου Κρήτης, Μάρτιος 2005 – Ιούνιος 2008.

6. ΘΕΣΕΙΣ ΣΤΟ ΕΞΩΤΕΡΙΚΟ

- i) Registrar Gastroenterologist, Royal United Hospital, Bath, England, (Ιούνιος 1990 – Ιούλιος 1991).
- ii) Consultant Gastroenterologist, Royal United Hospital, Bath, England, (Ιανουάριος 1998 – Δεκέμβριος 2000).
- iii) Senior Clinical Research Fellow, Department of Pharmacy and Pharmacology, University of Bath, UK (Ιανουάριος 1998 – Δεκέμβριος 2000).
- iv) Researcher, Novartis Pharmaceuticals Ltd United Kingdom, (Ιούνιος 1999 – Νοέμβριος 2000).
- v) Visiting Scientist (Sabbatical), Laboratory of Molecular Immunology, Mucosal Immunobiology Section, National Institute of Health (NIH), Bethesda, Maryland, U.S.A. (Ιανουάριος 2007-Νοέμβριος 2007).
- vi) Visiting Scientist (Sabbatical), Immunology Institute, Mount Sinai School of Medicine, U.S.A. (Νοέμβριος 2007-Φεβρουάριος 2008).

7. ΣΥΜΜΕΤΟΧΗ ΣΕ ΕΠΙΣΤΗΜΟΝΙΚΕΣ ΕΤΑΙΡΕΙΕΣ:

- i) Μέλος της Ελληνικής Γαστρεντερολογικής Εταιρείας (November 1990).
- ii) Μέλος της British Society for Immunology (November 1998).
- iii) Μέλος της European Society of Gastrointestinal and Abdominal Radiology (May 2005).
- iv) Μέλος της Society for Mucosal Immunology (September 2007).
- v) Μέλος της European Crohn's and Colitis Organization (May 2008).
- vi) Μέλος της Ελληνικής Φαρμακολογικής Εταιρείας (Φεβρουάριος 2009).

8. ΕΡΕΥΝΗΤΙΚΕΣ ΧΡΗΜΑΤΟΔΟΤΗΣΕΙΣ

- i) Chemokine production by human colonic epithelial cells in inflammatory bowel disease (National Association for Crohn and Colitis, UK 1994; £ 35.000).
- ii) Chemokine expression in the mucosa of inflammatory bowel disease patients; modulation by T-cell derived cytokines (Υποτροφία Ελληνικής Γαστρεντερολογικής Εταιρείας 1995; 3.000.000 Δρχ)
- iii) Mechanisms of mucosal injury in inflammatory bowel disease (Astra Foundation, UK 1996; £55.000)
- iv) Regulation of chemokines and inducible nitric oxide synthase by cytokines in Inflammatory Bowel Disease (Astra Foundation, UK 1997; £55,000).
- v) The role of chemokines in the fibrotic process in inflammatory bowel disease (Novartis, UK 1999; £ 120.000)
- vi) Investigate the cross-talk between colonic epithelial cells, intraepithelial lymphocytes and myofibroblasts and its relevance to inflammatory bowel disease. (Wellcome Trust, UK 2002; £ 15.000).
- vii) Πρόγραμμα ΠΥΘΑΓΟΡΑΣ II: «Η επίδραση των χημειοκινών στη διεργασία της ίνωσης στη νόσο του Crohn. Ο ρόλος των μυοϊνοβλαστών» (Κ.Α 2094, 45200 ευρώ, Ιούνιος 2005).
- viii) Ο ρυθμιστικός ρόλος των αγγειογενετικών και αγγειοστατικών C-X-C χημειοκινών στον καρκίνο του παχέος εντέρου. Παράγοντες ρύθμισης της αύξησης και των μεταστάσεων του όγκου. (Υπουργείο Υγείας και πρόνοιας 12.000 ευρώ, 2006-2008).

- ix) Μέλος της επιστημονικής ομάδας του επιχειρησιακού προγράμματος «Ανάπτυξη Ανθρωπίνου Δυναμικού» κατηγορία παρεμβάσεων : προάσπιση της δημόσιας υγείας του πληθυσμού, Άξονας Προτεραιότητας 13: με τίτλο: «Βλαπτικές επιπτώσεις της χρήσης φυτοπροστατευτικών προϊόντων: εξειδικευμένοι βιοδείκτες στην υπηρεσία της Δημόσιας Υγείας και εκστρατεία ενημέρωσης». (Επ. Υπεύθυνος: Χατζάκη Αικατερίνη, Επικ. Καθηγήτρια ΔΠΘ, 2007-2013).
- x) Μέλος της επιστημονικής ομάδας του επιχειρησιακού προγράμματος ΔΡΑΣΗ ΕΘΝΙΚΗΣ ΕΜΒΕΛΕΙΑΣ «ΣΥΝΕΡΓΑΣΙΑ» με τίτλο «Διερεύνηση νέων φλεγμονωδών μηχανισμών σε χρόνια αυτοφλεγμονώδη και αυτοάνοσα νοσήματα όπως ο οικογενής Μεσογειακός πυρετός και άλλα περιοδικά σύνδρομα πυρετού, η ου-ρική αρθρίτιδα, η νόσος του Crohn, η ρευματοειδής αρθρίτιδα και οι υπότυποι της όπως η νόσος του Still». (Επ. Υπεύθυνος: Δημήτριος Μπούμπας, Καθηγητής ΕΚΠΑ, 2011-2014).
- xi) Διαταραχές της έκφραση των υποδοχέων των χημειοκινών στην ιδιοπαθή πνευμονική ίνωση και την πνευμονική υπέρταση. Σε συνεργασία με τον Καθηγητή κ. Δημοσθένη Μπούρο (GlaxoSmithKline, Greece, 75,000 ευρώ, 2009-2012)

9. ΕΠΙΛΕΓΜΕΝΕΣ ΔΗΜΟΣΙΕΥΣΕΙΣ:

- 1) **Kolios G**, Brown Z, Robson RL, Robertson DAF, Westwick J. Inducible nitric oxide synthase activity and expression in a human colonic epithelial cell line, HT-29. **British Journal of Pharmacology** 1995; 116:2866-2872.
- 2) **Kolios G**, Kaloterakis A, Filiotou A, Nakos A, Hadziyannis S. Gastroscopic findings in Mediterranean Kaposi's sarcoma (non-AIDS). **Gastrointestinal Endoscopy** 1995; 42:336-339.
- 3) **Kolios G**, Robertson DAF, Jordan NJ, Minty A, Caput D, Ferrara P, Westwick J. Interleukin-8 production by the human colon epithelial cell line HT-29: Modulation by interleukin -13. **British Journal of Pharmacology** 1996; 119:351-359.
- 4) Wright K, Ward SG, **Kolios G**, Westwick J. Activation of phosphatidylinositol 3-kinase by interleukin-13. An inhibitory signal for inducible nitric-oxide synthase expression in epithelial cell line HT-29. **Journal of Biological Chemistry** 1997; 272:12626-12633.
- 5) Davis AJ, **Kolios G**, Alveyn CG, Robertson DA. Antibiotic prophylaxis for ERCP: a comparison of oral ciprofloxacin with intravenous cephalosporin in the prophylaxis of high-risk patients. **Alimentary Pharmacology and Therapeutics** 1998; 12:207-211.
- 6) **Kolios G**, Rooney N, Murphy CT, Robertson DAF, Westwick J. Expression of inducible nitric oxide synthase activity in human colon epithelial cells: Modulation by T-lymphocyte derived cytokines. **Gut** 1998; 43:56-63.
- 7) **Kolios G**, Petoumenos C, Nakos A. Mediators of inflammation: production and implication in inflammatory bowel disease. **Hepatogastroenterology** 1998; 45:1601-1609.

- 8) Jordan NJ, **Kolios G**, Abbot SE, Sinai MA, Thompson DA, Petraki K, Westwick J. Expression of functional CXCR4 chemokine receptors on human colonic epithelial cells. *Journal of Clinical Investigation* 1999; 104:1061-1069.
- 9) **Kolios G**, Wright KL, Jordan NJ, Leithead BJ, Robertson DAF, Westwick J. C-X-C and C-C chemokine expression and secretion by the human colonic epithelial cell line, HT-29: Differential effect of T-lymphocyte derived cytokines. *European Journal of Immunology* 1999; 29:530-536.
- 10) Wright K, **Kolios G**, Westwick J, Ward SG. Cytokine-induced apoptosis in epithelial HT-29 cells is independent of nitric oxide formation. Evidence for an interleukin-13-driven phosphatidylinositol 3-kinase-dependent survival mechanism. *Journal of Biological Chemistry* 1999; 274:17193-17201.
- 11) **Kolios G**, Wright KL, Linehan JD, Robertson DA, Westwick J. Interleukin-13 inhibits nitric oxide production in human colonic mucosa. *Hepatogastroenterology* 2000; 47:714-717.
- 12) Weaver SA, Russo MP, Wright KL, **Kolios G**, Jobin C, Robertson DA, Ward SG. Regulatory role of phosphatidylinositol 3-kinase on TNF-alpha-induced cyclooxygenase 2 expression in colonic epithelial cells. *Gastroenterology* 2001; 120:1117-1127.
- 13) **Kolios G**, Valatas V, Psilopoulos D, Petraki K, Kouroumalis E. Depletion of non specific esterase activity in the colonic mucosa of patients with ulcerative colitis. *European Journal of Clinical Investigation* 2002; 32:265-273.
- 14) Valatas V, Xidakis C, Roumpaki H, **Kolios G**, Kouroumalis EA. Isolation of rat Kupffer cells: a combined methodology for highly purified primary cultures. *Cell Biology International* 2003; 27:67-73.
- 15) Kolios G, Valatas V, Ward SG. Nitric oxide in inflammatory bowel disease: a universal messenger in an unsolved puzzle. *Immunology* 2004; 113:427-437.
- 16) Koutroubakis IE, Theodoropoulou A, Xidakis C, Sfiridaki A, Notas G, **Kolios G**, Kouroumalis EA. Association between enhanced soluble CD40 ligand and prothrombotic state in inflammatory bowel disease. *European Journal of Gastroenterology and Hepatology* 2004; 16:1147-1152.
- 17) Notas G, **Kolios G**, Mastrodimou N, Kampa M, Vasilaki A, Xidakis C, Castanas E, Thermos K, Kouroumalis E. Cortistatin production by HepG2 human hepatocellular carcinoma cell line and distribution of somatostatin receptors. *Journal of Hepatology* 2004; 40:792-798.
- 18) Valatas V, **Kolios G**, Manousou P, Notas G, Xidakis C, Diamantis I, Kouroumalis E. Octreotide regulates CC but not CXC LPS-induced chemokine secretion in rat Kupffer cells. *British Journal of Pharmacology* 2004; 141:477-487.

- 19) Valatas V, **Kolios G**, Manousou P, Xidakis C, Notas G, Ljumovic D, Kouroumalis EA. Secretion of inflammatory mediators by isolated rat Kupffer cells: the effect of octreotide. *Regulatory Peptides* 2004; 120:215-225.
- 20) Vasilaki A, Papadaki T, Notas G, **Kolios G**, Mastrodimou N, Hoyer D, Tsilimbaris M, Kouroumalis E, Pallikaris I, Thermos K. Effect of somatostatin on nitric oxide production in human retinal pigment epithelium cell cultures. *Investigative Ophthalmology & Visual Science* 2004; 45:1499-1506.
- 21) Wright KL, Weaver SA, Patel K, Coopman K, Feeney M, **Kolios G**, Robertson DA, Ward SG. Differential regulation of prostaglandin E biosynthesis by interferon-gamma in colonic epithelial cells. *British Journal of Pharmacology* 2004; 141:1091-1097.
- 22) Xidakis C, **Kolios G**, Valatas V, Notas G, Mouzas I, Kouroumalis E. Effect of octreotide on apoptosis-related proteins in rat Kupffer cells: a possible anti-tumour mechanism. *Anticancer Research* 2004; 24:833-841.
- 23) Dimoulios P, **Kolios G**, Notas G, Matrella E, Xidakis C, Koulentaki M, Tsagarakis N, Kouroumalis A, Kouroumalis E. Ursodeoxycholic acid reduces increased circulating endothelin 2 in primary biliary cirrhosis. *Alimentary Pharmacology and Therapeutics* 2005; 21:227-234.
- 24) Kouroumalis A, Nibbs RJ, Aptel H, Wright KL, **Kolios G**, Ward SG. The Chemokines CXCL9, CXCL10, and CXCL11 Differentially Stimulate G{alpha}i-Independent Signaling and Actin Responses in Human Intestinal Myofibroblasts. *Journal of Immunology* 2005; 175:5403-5411.
- 25) Linehan JD, **Kolios G**, Valatas V, Robertson DA, Westwick J. Immunomodulatory cytokines suppress epithelial nitric oxide production in inflammatory bowel disease by acting on mononuclear cells. *Free Radical Biology & Medicine* 2005; 39:1560-1569.
- 26) Linehan JD, **Kolios G**, Valatas V, Robertson DA, Westwick J. Effect of corticosteroids on nitric oxide production in inflammatory bowel disease: are leukocytes the site of action? *American Journal Physiology - Gastrointestinal & Liver Physiology* 2005; 288:G261-G267.
- 27) Xidakis C, Ljumovic D, Manousou P, Notas G, Valatas V, **Kolios G**, Kouroumalis E. Production of pro- and anti-fibrotic agents by rat Kupffer cells; the effect of octreotide. *Digestive Diseases and Sciences* 2005; 50:935-941.
- 28) Charalampopoulos I, Androulidaki A, Minas V, Chatzaki E, Tsatsanis C, Notas G, Xidakis C, **Kolios G**, Kouroumalis E, Margioris AN, Gravanis A. Neuropeptide urocortin and its receptors are expressed in rat kupffer cells. *Neuroendocrinology* 2006; 84:49-57.
- 29) **Kolios G**, Valatas V, Kouroumalis E. Role of Kupffer cells in the pathogenesis of liver disease. *World Journal of Gastroenterology* 2006; 12:7413-7420.

- 30) **Kolios G**, Manousou P, Bourikas L, Notas G, Tsagarakis N, Mouzas I, Kouroumalis E. Ciprofloxacin inhibits cytokine-induced nitric oxide production in human colonic epithelium. *European Journal of Clinical Investigation* 2006; 36:720-729.
- 31) **Kolios G**, Kotzampassi K, Manousou P, Paramythiotis D, Papanastasiou H, Drygiannakis I, Notas G, Tsagarakis N, Eleftheriadis E, Kouroumalis E. Enteral nutrition affects nitric oxide production in peripheral blood and liver after a postoperative lipopolysaccharide-induced endotoxemia in rats. *Nutrition* 2007; 23:575-581.
- 32) Xidakis C, Mastrodimitrou N, Notas G, Renieri E, **Kolios G**, Kouroumalis E, Thermos K. RT-PCR and immunocytochemistry studies support the presence of somatostatin, cortistatin and somatostatin receptor subtypes in rat Kupffer cells. *Regulatory Peptides* 2007; 143:76-82.
- 33) Damaskos D, **Kolios G**. Probiotics and prebiotics in inflammatory bowel disease: microflora 'on the scope'. *British Journal of Clinical Pharmacology* 2008; 65:453-467.
- 34) **Kolios G**, Valatas V, Manousou P, Xidakis C, Notas G, Kouroumalis E. Nitric oxide and MCP-1 regulation in LPS activated rat Kupffer cells. *Molecular and Cellular Biochemistry* 2008; 319:91-98.
- 35) Manousou P, **Kolios G**, Drygiannakis I, Pyrovolaki K, Bourikas L, Papadaki HA, Kouroumalis E. Expression of a splice variant of CXCR3 in Crohn's disease patients; indication for a lymphocyte--epithelial cell interaction. *Journal of Gastroenterology and Hepatology* 2008; 23:1823-1833.
- 36) Bourikas LA, **Kolios G**, Valatas V, Notas G, Drygiannakis I, Pelagiadis I, Manousou P, Klironomos S, Mouzas IA, Kouroumalis E. Ciprofloxacin decreases survival in HT-29 cells via the induction of TGF-beta1 secretion and enhances the anti-proliferative effect of 5-fluorouracil. *British Journal of Pharmacology* 2009; 157:362-370.
- 37) Galazios G, Papazoglou D, Tsikouras P, **Kolios G**. Vascular endothelial growth factor gene polymorphisms and pregnancy. *Journal of Maternal-Fetal & Neonatal Medicine* 2009; 22:371-378.
- 38) Kotzampassi K, **Kolios G**, Manousou P, Kazamias P, Paramythiotis D, Papavramidis TS, Heliadis S, Kouroumalis E, Eleftheriadis E. Oxidative stress due to anesthesia and surgical trauma: Importance of early enteral nutrition. *Molecular Nutrition & Food Research* 2009; 53:770-779.
- 39) Paschos KA, **Kolios G**, Chatzaki E. The corticotropin-releasing factor system in inflammatory bowel disease: Prospects for new therapeutic approaches. *Drug Discovery Today* 2009; 14:713-720.
- 40) Kefalakes E, Stylianides TJ, Amanakis G, **Kolios G**. Exacerbation of Inflammatory Bowel Diseases associated with the use of nonsteroidal anti-inflammatory drugs: Myth or Reality? *European Journal of Clinical Pharmacology* 2009; 65:963-70.

- 41) Tsagarakis NJ, Drygiannakis I, Batistakis AG, **Kolios G**, Kouroumalis EA. A concentration dependent effect of Ursodeoxycholate on apoptosis and caspases activities of HepG2 hepatocellular carcinoma cells. *European Journal of Pharmacology* 2010; 640:1-7.
- 42) Manousou P, Kolios G, Valatas V, Drygiannakis I, Bourikas L, Pyrovolaki K, Koutroubakis I, Papadaki HA, Kouroumalis E. Increased expression of Chemokine receptor CCR3 and its ligands in ulcerative colitis; the role of colonic epithelial cells in in vitro studies. *Clinical & Experimental Immunology* 2010; 162:337–347.
- 43) Kapetanakis S, Drygiannakis I, Kazakos K, Papanas N, **Kolios G**, Kouroumalis E, Verettas DA. Serum TGF- β 2 and TGF- β 3 are increased and positively correlated to pain, functionality and radiographic staging in osteoarthritis. *Orthopedics* 2010; 33:551.
- 44) Tsagarakis NJ, Drygiannakis I, Batistakis AG, **Kolios G**, Kouroumalis EA. Octreotide induces caspase activation and apoptosis in human hepatoma cells (HepG2). *World Journal of Gastroenterology* 2011; 17: 313-321.
- 45) Kambas K, Chrysanthopoulou A, Kourtzelis I, Skordala M, Mitroulis I, Rafail S, Vradelis S, Sigalas I, Wu YQ, Speletas M, **Kolios G**, Ritis K. Endothelin-1 signaling promotes fibrosis in vitro in a bronchopulmonary dysplasia model by activating the extrinsic coagulation cascade. *J Immunology* 2011; 186:6568-6575.
- 46) **Kolios G**, Lira SA. Chemokines and their receptors in gut homeostasis and disease. *Current Immunology Reviews* 2011; 7:271-279.
- 47) Chrysanthopoulou A, Mitroulis I, Kambas K, Skendros P, Kourtzelis I, Vradelis S, **Kolios G**, Aslanidis S, Doumas M, Ritis K. Tissue factor-thrombin signaling enhances the fibrotic activity of myofibroblasts in systemic sclerosis through endothelin-1 receptor A up-regulation. *Arthritis & Rheumatism* 2011; 63:3586-3597.
- 48) Tzouvelekis A, Bouros E, Oikonomou A, Ntolios P, Zacharis G, **Kolios G**, Bouros D. Effect and safety of Mycophenolate Mofetil in Idiopathic Pulmonary Fibrosis. *Pulmonary Medicine* 2011; 2011:849035.
- 49) Tzouvelekis A, Koliakos G, Ntolios P, Baira I, Bouros E, Oikonomou A, Zissimopoulos A, Boussios N, **Kolios G**, Paspaliaris V, Kakagia D, Kotsianidis I, Froudarakis M, Bouros D. Stem cell therapy for Idiopathic Pulmonary Fibrosis. A protocol proposal. *Journal of Translational Medicine* 2011; 9:182.
- 50) Tzouvelekis A, Galanopoulos N, Bouros E, **Kolios G**, Zacharis G, Ntolios P, Koulelidis A, Oikonomou A, Bouros D. Effect and safety of Mycophenolate mofetil or sodium in systemic sclerosis - associated interstitial lung disease. A meta-analysis. *Pulmonary Medicine* 2012; 2012:143637.

- 51) Domvri K, Zarogoulidis P, Porpodis K, Koffa M, Lambropoulou M, Kakolyris S, **Kolios G**, Zarogoulidis K, Chatzaki E. Gene therapy in liver diseases: State-of-the-art and future perspectives. *Current Gene Therapy* 2012; 12:463-483.
- 52) Drygiannakis I, Valatas V, Sfakianaki O, Bourikas L, Manousou P, Kambas K, Ritis K, **Kolios G**, Kouroumalis E. Proinflammatory cytokines induce crosstalk between colonic epithelial cells and subepithelial myofibroblasts: implication in intestinal fibrosis. *Journal of Crohn's and Colitis* 2013; 7:286-300.
- 53) Valatas V, He J, Rivollier A, **Kolios G**, Kitamura K, Kelsall BL. Host-dependent control of early regulatory and effector T cell differentiation underlies the genetic susceptibility of RAG2-deficient mouse strains to transfer colitis. *Mucosal Immunology* 2013; 6:601-611.
- 54) **Kolios G**, Moodley Y. Introduction to Stem Cells and Regenerative Medicine. *Respiration* 2013; 85:3-10.
- 55) Manousou P, **Kolios G**, Drygiannakis I, Koulentaki M, Pyrovolaki K, Voumvouraki A, Notas G, Bourikas L, Papadaki HA, Kouroumalis E. CXCR3 axis in patients with Primary Biliary Cirrhosis. The effect of Ursodeoxycholic Acid. *Clinical & Experimental Immunology* 2013; 172:9-15.
- 56) Chatzaki E, Anton PA, Million M, Lambropoulou M, Costantinidis T, **Kolios G**, Taché Y, Grigoriadis DE. CRF Receptor 2 in human colonic mucosa: down-regulation in Ulcerative Colitis. *World Journal of Gastroenterology* 2013; 19:1416-1423.
- 57) Pazaitou-Panayiotou K, Chemonidou C, Poupri A, Koureta M, Kaprara A, Lambropoulou M, Constantinidis TC, Galaktidou G, Koffa M, Kiziridou A, Kakolyris S, **Kolios G**, Kortsaris A, Chatzaki E. Gonadotropin-Releasing Hormone neuropeptides and receptor in human breast cancer: correlation to poor prognosis parameters. *Peptides* 2013; 42:15-24.
- 58) Balgkouranidou I, Karayiannakis A, Matthaïos D, Bolanaki H, Tripsianis G, Tentes AA, Lianidou E, Chatzaki E, Fiska A, Lambropoulou M, **Kolios G**, Kakolyris S. Assessment of SOX17 DNA methylation in cell free DNA from patients with operable gastric cancer. Association with prognostic variables and survival. *Clinical Chemistry and Laboratory Medicine* 2013; 51:1505-1510.
- 59) Paschos KA, Chouridou E, Koureta M, Lambropoulou M, **Kolios G**, Chatzaki E. The Corticotropin Releasing Factor system in the liver: expression, actions and possible implications in hepatic physiology and pathology. *Hormones (Athens)* 2013; 12:236-245
- 60) Drosos I, **Kolios G**. Stem cells in liver regeneration and their potential clinical applications. *Stem Cell Reviews and Reports* 2013; 9:668-684.

- 61) Tzouvelekis A, Paspaliaris V, Koliakos G, Ntoliou P, Bouros E, Oikonomou A, Zissimopoulos A, Boussios N, Dardzinski B, Gritzalis D, Antoniadis A, Froudarakis M, **Kolios G**, Bouros D. A prospective, non-randomized, no placebo-controlled, phase Ib clinical trial to study the safety of the adipose derived stromal cells-stromal vascular fraction in Idiopathic Pulmonary Fibrosis. *Journal of Translational Medicine* 2013; 11:171.
- 62) Valatas V, Vakas M, **Kolios G**. The value of experimental models of colitis in predicting efficacy of biological therapies for inflammatory bowel diseases. *American Journal of Physiology, Gastrointestinal Liver Physiology* 2013; 305:G763-G785.

Δεκέμβριος 2013

Γεώργιος Κολιός, MD PhD